Azilsartan Mitigates Dextran Sulfate-induced Colitis in Rats via Modulating Inflammation and Oxidative Stress
DOI:
https://doi.org/10.54133/ajms.v10i1.2478Keywords:
Anti-inflammatory activity , Azilsartan , Dextran sulfate , Ulcerative colitisAbstract
Background: Ulcerative colitis is a persistent mucosal inflammation of the bowel that impacts a high portion of the population worldwide. It often presents with symptoms of severe diarrhea, weight reduction, and perianal bleeding. Objective: To investigate the potential anti-inflammatory effects of azilsartan on dextran sulfate-induced ulcerative colitis in rats. Methods: Forty healthy adult albino rats were divided into 4 groups, as follows: the normal control group, the DSS group, DSS+ prednisolone (10 mg/kg/day) group, and DSS+azilsartan (10 mg/kg/day) group. The colitis induction was prompted in rats by administering 3% DSS in drinking water for 7 days. Results: The administration of azilsartan notably decreased edema index, spleen index, macroscopic changes scores, and microscopic changes scores that were produced by DSS. Additionally, azilsartan markedly reduced the proinflammatory cytokine expression, including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in colon tissue. Furthermore, azilsartan significantly attenuated oxidative stress in colonic tissue by decreasing up-regulated myeloperoxidase (MPO) enzyme activity and increasing down-regulated catalase antioxidant activity. Conclusions: Azilsartan may have an effective role in the treatment of ulcerative colitis.
Downloads
References
Feng X, Xie Q, Xu H, Zhang T, Li X, Tian Y, et al. Yeast microcapsule mediated natural products delivery for treating ulcerative colitis through anti-inflammatory and regulation of macrophage polarization. ACS Appl Material Interfac. 2022;14(27):31085-31098. doi: 10.1021/acsami.2c05642. DOI: https://doi.org/10.1021/acsami.2c05642
Aleisa AM, Al-Rejaie SS, Abuohashish HM, Ola MS, Parmar MY, Ahmed MM. Pretreatment of Gymnema sylvestre revealed the protection against acetic acid-induced ulcerative colitis in rats. BMC Complement Alternat Med. 2014;14(1):49. doi: 10.1186/1472-6882-14-49. DOI: https://doi.org/10.1186/1472-6882-14-49
Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative colitis—diagnostic and therapeutic algorithms. Deutsches Ärzteblatt Int. 2020;117(33-34):564. doi: 10.3238/arztebl.2020.0564. DOI: https://doi.org/10.3238/arztebl.2020.0564
Owusu G, Obiri DD, Ainooson GK, Osafo N, Antwi AO, Duduyemi BM, et al. Acetic acid‐induced ulcerative colitis in Sprague Dawley rats is suppressed by hydroethanolic extract of Cordia vignei leaves through reduced serum levels of TNF‐α and IL‐6. Int J Chronic Dis. 2020;2020(1):8785497. doi: 10.1155/2020/8785497. DOI: https://doi.org/10.1155/2020/8785497
Silva FA, Rodrigues BL, Ayrizono MD, Leal RF. The immunological basis of inflammatory bowel disease. Gastroenterol Res Pract. 2016;2016(1):2097274. doi: 10.1155/2016/2097274. DOI: https://doi.org/10.1155/2016/2097274
Shahid M, Raish M, Ahmad A, Bin Jardan YA, Ansari MA, Ahad A, et al. Sinapic acid ameliorates acetic acid-induced ulcerative colitis in rats by suppressing inflammation, oxidative stress, and apoptosis. Molecules. 2022;27(13):4139. doi: 10.3390/molecules27134139. DOI: https://doi.org/10.3390/molecules27134139
Grenier L, Hu P. Computational drug repurposing for inflammatory bowel disease using genetic information. Comput Struct Biotechnol J. 2019;17:127-135. doi: 10.1016/j.csbj.2019.01.001.
Hoofnagle JH, (Ed.), LiverTox: Clinical and Research Information on Drug‑Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
Zaiken K, Cheng JW. Azilsartan medoxomil: a new angiotensin receptor blocker. Clin Ther. 2011;33(11):1577-1589. doi: 10.1016/j.clinthera.2011.10.007. DOI: https://doi.org/10.1016/j.clinthera.2011.10.007
Pradhan A, Tiwari A, Sethi R. Azilsartan: current evidence and perspectives in management of hypertension. Int J Hypertens. 2019;2019(1):1824621. doi: 10.1155/2019/1824621. DOI: https://doi.org/10.1155/2019/1824621
Sukumaran V, Tsuchimochi H, Tatsumi E, Shirai M, Pearson JT. Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1–7/Mas receptor cascade. Biochem Pharmacol. 2017;144:90-99. doi: 10.1016/j.bcp.2017.07.022. DOI: https://doi.org/10.1016/j.bcp.2017.07.022
Al-Chlaihawi M, Janabi A. Azilsartan improves doxorubicin-induced cardiotoxicity via inhibiting oxidative stress, proinflammatory pathway, and apoptosis. J Med Life. 2023;16(12):1783-1788. doi: 10.25122/jml-2023-0106. DOI: https://doi.org/10.25122/jml-2023-0106
Dong Q, Li Y, Chen J, Wang N. Azilsartan suppressed LPS-induced inflammation in U937 macrophages through suppressing oxidative stress and inhibiting the TLR2/MyD88 signal pathway. ACS Omega. 2020;6(1):113-118. doi: 10.1021/acsomega.0c03655. DOI: https://doi.org/10.1021/acsomega.0c03655
Jaworska K, Koper M, Ufnal M. Gut microbiota and renin-angiotensin system: A complex interplay at local and systemic levels. Am J Physiol Gastroint Liver Physiol. 2021;321(4):G355-366. doi: 10.1152/ajpgi.00099.2021. DOI: https://doi.org/10.1152/ajpgi.00099.2021
Yamane S, Amano H, Ito Y, Betto T, Inoue T, Otaka F, et al. The role of angiotensin II type 1A receptor signaling in gastric ulcer healing. Kitasato Med J. 2019;49:52-63.
Bregonzio C, Armando I, Ando H, Jezova M, Baiardi G, Saavedra JM. Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. Am J Physiol Gastrointes Liver Physiol. 2003;285(2):G414-423. doi: 10.1152/ajpgi.00058.2003. DOI: https://doi.org/10.1152/ajpgi.00058.2003
Shi Y, Liu T, He L, Dougherty U, Chen L, Adhikari S, et al. Activation of the renin-angiotensin system promotes colitis development. Sci Rep. 2016;6(1):27552. doi: 10.1038/srep27552. DOI: https://doi.org/10.1038/srep27552
Khajah MA, Fateel MM, Ananthalakshmi KV, Luqmani YA. Anti-inflammatory action of angiotensin 1-7 in experimental colitis. PLoS One. 2016;11(3):e0150861. doi: 10.1371/journal.pone.0150861. DOI: https://doi.org/10.1371/journal.pone.0150861
Saber S, Basuony M, Eldin AS. Telmisartan ameliorates dextran sodium sulfate-induced colitis in rats by modulating NF-κB signalling in the context of PPARγ agonistic activity. Arch Biochem Biophys. 2019;671:185-195. doi: 10.1016/j.abb.2019.07.014. DOI: https://doi.org/10.1016/j.abb.2019.07.014
Saber S, Khalil RM, Abdo WS, Nassif D, El-Ahwany E. Olmesartan ameliorates chemically-induced ulcerative colitis in rats via modulating NFκB and Nrf-2/HO-1 signaling crosstalk. Toxicol Appl Pharmacol. 2019;364:120-132. doi: 10.1016/j.taap.2018.12.020. DOI: https://doi.org/10.1016/j.taap.2018.12.020
De Caterina AR, Harper AR, Cuculi F. Critical evaluation of the efficacy and tolerability of azilsartan. Vasc Health Risk Manag. 2012;8:299-305. doi: 10.2147/VHRM.S22589. DOI: https://doi.org/10.2147/VHRM.S22589
Matsumoto S, Shimabukuro M, Fukuda D, Soeki T, Yamakawa K, Masuzaki H, et al. Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice. Cardiovasc Diabetol. 2014;13:30. doi: 10.1186/1475-2840-13-30. DOI: https://doi.org/10.1186/1475-2840-13-30
Jeon YD, Lee JH, Lee YM, Kim DK. Puerarin inhibits inflammation and oxidative stress in dextran sulfate sodium-induced colitis mice model. Biomed Pharmacother. 2020;124:109847. doi: 10.1016/j.biopha.2020.109847. DOI: https://doi.org/10.1016/j.biopha.2020.109847
Hama Amin RR, Aziz TA. Gastroprotective effect of azilsartan through ameliorating oxidative stress, inflammation, and restoring hydroxyproline, and gastrin levels in ethanol-induced gastric ulcer. J Inflamm Res. 2022:2911-2923. doi: 10.2147/JIR.S365090. DOI: https://doi.org/10.2147/JIR.S365090
Wang G, Xu B, Shi F, Du M, Li Y, Yu T, et al. Protective effect of methane‐rich saline on acetic acid‐induced ulcerative colitis via blocking the TLR4/NF‐κB/MAPK pathway and promoting IL‐10/JAK1/STAT3‐mediated anti‐inflammatory response. Oxid Med Cell Longev. 2019;2019(1):7850324. doi: 10.1155/2019/7850324. DOI: https://doi.org/10.1155/2019/7850324
Appleyard CB, Wallace JL. Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol Gastrointest Liver Physiol. 1995;269(1):G119-125. doi: 10.1152/ajpgi.1995.269.1.G119. DOI: https://doi.org/10.1152/ajpgi.1995.269.1.G119
Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Investig Dermatol. 1982;78(3):206-209. doi: 10.1111/1523-1747.ep12506462. DOI: https://doi.org/10.1111/1523-1747.ep12506462
Goth L. A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta. 1991;196(2-3):143-151. doi: 10.1016/0009-8981(91)90067-m. DOI: https://doi.org/10.1016/0009-8981(91)90067-M
Slaoui M, Bauchet AL, Fiette L. Tissue sampling and processing for histopathology evaluation. Methods Mol Biol. 2017;1641:101-114. doi:10.1007/978-1-4939-7172-5_4. DOI: https://doi.org/10.1007/978-1-4939-7172-5_4
Gaudio E, Taddei G, Vetuschi A, Sferra R, Frieri G, Ricciardi G, et al. Dextran sulfate sodium (DSS) colitis in rats (clinical, structural, and ultrastructural aspects). Digest Dis Sci. 1999;44(7):1458-1475. doi: 10.1023/a:1026620322859. DOI: https://doi.org/10.1023/A:1026620322859
Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford). 2004;43(3):294-301. doi: 10.1093/rheumatology/keh058. DOI: https://doi.org/10.1093/rheumatology/keh058
Indrayan A. Medical biostatistics as a science of managing nedical uncertainties. Indian J Community Med. 2021;46(2):182-185. doi: 10.4103/ijcm.IJCM_763_20.
Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(1):91-99. doi: 10.3748/wjg.v20.i1.91. DOI: https://doi.org/10.3748/wjg.v20.i1.91
Grenier L, Hu P. Computational drug repurposing for inflammatory bowel disease using genetic information. Comput Struct Biotechnol J. 2019;17:127-135. doi: 10.1016/j.csbj.2019.01.001. DOI: https://doi.org/10.1016/j.csbj.2019.01.001
Chassaing B, Aitken JD, Malleshappa M, Vijay‐Kumar M. Dextran sulfate sodium (DSS)‐induced colitis in mice. Curr Protocol Immunol. 2014;104(1):15-25. doi: 10.1002/0471142735.im1525s104. DOI: https://doi.org/10.1002/0471142735.im1525s104
Arda-Pirincci P, Aykol-Celik G. Galectin-1 reduces the severity of dextran sulfate sodium (DSS)-induced ulcerative colitis by suppressing inflammatory and oxidative stress response. Bosnian J Basic Med Sci. 2020;20(3):319. doi: 10.17305/bjbms.2019.4539. DOI: https://doi.org/10.17305/bjbms.2019.4539
Li B, Du P, Du Y, Zhao D, Cai Y, Yang Q, et al. Luteolin alleviates inflammation and modulates gut microbiota in ulcerative colitis rats. Life Sci. 2021;269:119008. doi: 10.1016/j.lfs.2020.119008. DOI: https://doi.org/10.1016/j.lfs.2020.119008
Ding Q, Fang H, Jin P, Lv J, Ding S, Zhu W, et al. Pretreating mesenchymal stem cells with IL-6 regulates the inflammatory response of DSS-induced ulcerative colitis in rats. Transplant Immunol. 2023;76:101765. doi: 10.1016/j.trim.2022.101765. DOI: https://doi.org/10.1016/j.trim.2022.101765
Huang Y, Ma Z, Cui YH, Dong HS, Zhao JM, Dou CZ, et al. Effects of herb‐partitioned moxibustion on the miRNA expression profiles in colon from rats with DSS‐induced ulcerative colitis. Evidence‐Based Complement Alternat Med. 2017;2017(1):1767301. doi: 10.1155/2017/1767301. DOI: https://doi.org/10.1155/2017/1767301
Gupta RA, Motiwala MN, Mahajan UN, Sabre SG. Protective effect of Sesbania grandiflora on acetic acid induced ulcerative colitis in mice by inhibition of TNF-α and IL-6. J Ethnopharmacol. 2018;219:222-232. doi: 10.1016/j.jep.2018.02.043. DOI: https://doi.org/10.1016/j.jep.2018.02.043
Khashper A, Shwartz D, Taragin BH, Shalmon T. Splenic size as a marker for active inflammation in Crohn's disease. Clin Imag. 2022;84:164-167. doi: 10.1016/j.clinimag.2022.02.012. DOI: https://doi.org/10.1016/j.clinimag.2022.02.012
Kawashima K, Onizawa M, Fujiwara T, Gunji N, Imamura H, Katakura K, et al. Evaluation of the relationship between the spleen volume and the disease activity in ulcerative colitis and Crohn disease. Medicine. 2022;101(1):e28515. doi: 10.1097/MD.0000000000028515. DOI: https://doi.org/10.1097/MD.0000000000028515
Shi X, Wang JH, Rao SX, Liu TT, Wu H. A novel role of the splenic volume in Crohn’s disease: evaluating the efficacy of infliximab. Front Pharmacol. 2023;14:1246657. doi: 10.3389/fphar.2023.1246657. DOI: https://doi.org/10.3389/fphar.2023.1246657
Liu P, Li Y, Wang R, Ren F, Wang X. Oxidative Stress and Antioxidant Nanotherapeutic Approaches for Inflammatory Bowel Disease. Biomedicines. 2021 Dec 31;10(1):85. doi: 10.3390/biomedicines10010085. PMID: 35052764; PMCID: PMC8773244. DOI: https://doi.org/10.3390/biomedicines10010085
de Araújo AA, Varela H, de Medeiros CA, de Castro Brito GA, de Lima KC, de Moura LM, et al. Azilsartan reduced TNF-α and IL-1β levels, increased IL-10 levels and upregulated VEGF, FGF, KGF, and TGF-α in an oral mucositis model. PLoS One. 2015;10(2):e0116799. doi: 10.1371/journal.pone.0116799.. DOI: https://doi.org/10.1371/journal.pone.0116799
Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam. 2014;2014:689360. doi: 10.1155/2014/689360. DOI: https://doi.org/10.1155/2014/689360
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published by Al-Rafidain University College. This is an open access journal issued under the CC BY-NC-SA 4.0 license (https://creativecommons.org/licenses/by-nc-sa/4.0/).
